Acquired Immunodeficiency Syndrome in the Infant

Infectious Diseases of the Fetus and Newborn Infant

Volumn , Issue , 2006, Pages 667-692

  Maldonado, Yvonne A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750492276     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-72-160537-0/50023-2     Document Type: Chapter

References (381)

1. Unexplained immunodeficiency and opportunistic infections in infants-New York, New Jersey, California. MMWR Morb Mortal Wkly Rep 1982, 31:665-667. Centers for Disease Control,.
2. Ammann AJ, Cowan MJ, Wara DW, et al. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet 1983, 1:956-958.
3. Oleske J, Minnefor A, Cooper R, et al. Immune deficiency syndrome in children. JAMA 1983, 249:2345-2349.
4. Rubinstein A, Sicklick M, Gupta A, et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA 1983, 249:2350-2356.
5. HIV/AIDS Surveillance report 2002, 14:1-48. Centers for Disease Control and Prevention.
6. AIDS Epidemic Update 2003 2003, Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO), World Health Organization, Geneva.
7. Coleman RL, Wilkinson D Increasing HIV prevalence in a rural district of South Africa from 1992 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:50-53.
8. Laga M, De Cock KM, Kaleeba N, et al. HIV/AIDS in Africa: the second decade and beyond. AIDS 1997, 11:S1-S53.
9. Foster G Today's children-challenges to child health promotion in countries with severe AIDS epidemics. AIDS Care 1998, 10(Suppl 1):S17-S23.
10. Balter M United Nations: global program struggles to stem the flood of new cases. Science 1998, 280:1863-1864.
11. Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996, 10:1675-1681. The European Collaborative Study.
12. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:506-510. The Working Group on Mother-To-Child Transmission of HIV.
13. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996, 335:1621-1629.
14. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998, 178:101-108.
15. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402.
16. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001, 183:206-212. Epub Dec 15, 2000.
17. Montano M, Russell M, Gilbert P, et al. Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis 2003, 188:406-413. Epub Jul 14, 2003.
18. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
19. Connor EM, Mofenson LK Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: Pediatric AIDS Clinical Trials Group protocol 076-results and treatment recommendations. Pediatr Infect Dis J 1995, 14:536-541.
20. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994, 43:1-20. Centers for Disease Control and Prevention.
21. U.S. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 2002, 51(RR18):1-38. Centers for Disease Control and Prevention.
22. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999, 353:773-780.
23. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 6 1999, 353:781-785.
24. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
25. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003, 1362:859-868.
26. Nuovo GJ, Forde A, MacConnell P, Fahrenwald R In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol 1993, 143:40-48.
27. Royce RA, Sena A, Cates W, Cohen MS Sexual transmission of HIV. N Engl J Med 1997, 336:1072-1078.
28. Sprecher S, Soumenkoff G, Puissant F, Degueldre M Vertical transmission of HIV in 15-week fetus. Lancet 1986, 2:288-289.
29. Jovaisas E, Koch MA, Schäfer A, et al. LAV/HTLV-III in 20-week fetus. Lancet 1985, 2:1129.
30. Mano H, Chermann JC Fetal human immunodeficiency virus type 1 infection of different organs in the second trimester. AIDS Res Hum Retroviruses 1991, 7:83-88.
31. Mundy DC, Schinazi RF, Gerber AR, et al. Human immunodeficiency virus isolated from amniotic fluid. Lancet 1987, 2:459-460.
32. Lewis SH, Reynolds-Kohler C, Fox HE, Nelson JA HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet 1990, 335:565-568.
33. Amirhessami-Aghili N, Spector SA Human immunodeficiency virus type 1 infection of human placenta: Potential route for fetal infection. J Virol 1991, 65:2231-2236.
34. Zachar V, Thomas RA, Jones T, Goustin AS Vertical transmission of HIV: detection of proviral DNA in placental trophoblasts. AIDS 1994, 8:129-130.
35. Mattern CFT, Murray K, Jensen A, et al. Localization of human immunodeficiency virus core antigen in term human placentas. Pediatrics 1992, 89:207-209.
36. St.Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993, 269:2853-2859.
37. Thomas PA, Weedon J, Krasinski K, et al. Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatr Infect Dis J 1994, 13:489-495.
38. Borkowsky W, Krasinski K, Cao Y, et al. Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994, 125:345-351.
39. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A 1995, 92:12100-12104.
40. Mayaux MJ, Blanche S, Rouzioux C, et al. Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:188-194.
41. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nature Med 1997, 3:549-552.
42. Lambert G, Thea DM, Pliner V, et al. Effect of maternal CD4+ cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr 1997, 130:890-897.
43. D'Arminio Monforte A, Ravizza M, Muggiasca ML, et al. HIV-infected pregnant women: possible predictors of vertical transmission. Presented before the 7th International Conference on AIDS, Florence, Italy, 1991.
44. Peckham C, Gibb D Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995, 333:298-302.
45. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW Proposed definition for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992, 327:1246-1247.
46. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995, 142:1330-1337.
47. Nesheim SR, Shaffer N, Vink P, et al. Lack of increased risk for perinatal human immunodeficiency virus transmission to subsequent children born to infected women. Pediatr Infect Dis J 1996, 15:886-890.
48. Young KY, Nelson RP Discordant human immunodeficiency virus infection in dizygotic twins detected by polymerase chain reaction. Pediatr Infect Dis J 1990, 9:454-456.
49. Goedert JJ, Duliege AM, Amos CI, et al. High risk of HIV-1 infection for first-born twins. Lancet 1991, 338:1471-1475.
50. Duliege A-M, Amos CI, Felton S, et al. Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. J Pediatr 1995, 126:625-632.
51. Mofenson LM A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. Pediatr Infect Dis J 1995, 14:169-177.
52. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650.
53. Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997, 315:216-219.
54. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650.
55. Gaillard P, Mwanyumba F, Verhofstede C, et al. Vaginal lavage with chlorhexidine during labor to reduce mother-to-child HIV transmission: clinical trial in Mombassa, Kenya. AIDS 2001, 15:389-396.
56. Wilson CM, Gray G, Read JS, et al. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. J Acquir Immune Defic Syndr 2004, 35:138-143.
57. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999, 340:977-987. The International Perinatal HIV Group.
58. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996, 334:1617-1623.
59. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001, 15:357-368. International Perinatal HIV Group.
60. Van De Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1991, 325:593-598.
61. Van de Perre P, Simonon A, Hitimana D-G, et al. Infective and anti-infective properties of breast milk from HIV-1 infected women. Lancet 1993, 341:914-918.
62. Ruff AJ, Halsey NA, Coberly J, Boulos R Breast-feeding and maternal-infant transmission of human immunodeficiency virus type 1. J Pediatr 1992, 121:325-329.
63. Thiry L, Sprecher-Goldberger S, Jonckheer T, et al. Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet 1985, 2:891-892.
64. Lewis P, Nduati R, Kreiss JK, et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998, 177:34-39.
65. Guay LA, Hom DL, Mmiro F, et al. Detection of human immunodeficiency virus type 1 (HIV-1) DNA and p24 antigen in breast milk of HIV-1-infected Ugandan women and vertical transmission. Pediatrics 1996, 98:438-444.
66. de Martino M, Tovo P-A, Tozzi AE, et al. HIV-1 transmission through breast milk: appraisal of risk according to duration of feeding. AIDS 1992, 6:991-997.
67. Bertolli J, St.Louis ME, Simonds RJ, et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis 1996, 174:722-726.
68. Miotti PG, Taha TE, Kumwenda N, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999, 282:744-749.
69. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000, 283:1175-1182.
70. Lederman SA Estimating infant mortality from human immunodeficiency virus and other causes in breast-feeding and bottle-feeding populations. Pediatrics 1992, 89:290-296.
71. Bobat R, Moodley D, Coutsoudis A, Coovadia H Breastfeeding by HIV-1-infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS 1997, 11:1627-1633.
72. Read JS Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. Pediatrics 2003, 112:1196-1205. for the American Academy of Pediatrics Committee on Pediatric AIDS.
73. Friedland GH, Saltzman BR, Rogers MF, et al. Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis. N Engl J Med 1986, 314:334-339.
74. Mann JM, Quinn TC, Francis H, et al. Prevalence of HTLV-III/LAV in household contacts of patients with confirmed AIDS and controls in Kinshasa, Zaire. JAMA 1986, 256:721-724.
75. Human immunodeficiency virus transmission in household settings-United States. MMWR Morb Mortal Wkly Rep 1994, 43:347-356. Centers for Disease Control and Prevention.
76. Lobato MN, Oxtoby MJ, Augustyniak L, et al. Infection control practices in the home: a survey of households of HIV-infected persons with hemophilia. Infect Control Hosp Epidemiol 1996, 17:721-725.
77. Education of children with human immunodeficiency virus infection. Pediatrics 1991, 88:645-648. American Academy of Pediatrics Task Force of Pediatric AIDS.
78. Health guidelines for the attendance in day-care and foster care settings of children infected with human immunodeficiency virus. Pediatrics 1987, 79:466-470. Committee on Infectious Diseases.
79. Evaluation and medical treatment of the HIV-exposed infant. Pediatrics 1997, 99:909-917. American Academy of Pediatrics.
80. Zeichner SL The molecular biology of HIV: insights into pathogenesis and targets for therapy. Clin Perinatol 1994, 21:39-73.
81. Pavlakis GN The molecular biology of human immunodeficiency virus type 1. DeVita VT Jr, Hellman S, Rosenberg SA (eds): AIDS: Biology, Diagnosis, Treatment and Prevention 1997, 45-74. Lippincott-Raven, Philadelphia.
82. Cullen BR HIV-1 auxiliary proteins: making connections in a dying cell. Cell 1998, 93:685-692.
83. Fauci AS, Pantaleo G, Stanley S, Weissman D Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996, 124:654-663.
84. Feng Y, Broder CC, Kennedy PE, Berger EA HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877.
85. Cocchi F, DeVico AL, Garzino-Demo A, et al. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996, 2:1244-1247.
86. Kinter AL, Ostrowski M, Goletti D, et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between viral suppressive effects of endogenous β-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci U S A 1996, 93:14076-14081.
87. Lapham CK, Ouyang J, Chandrasekhar B, et al. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996, 274:602-605.
88. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
89. Rollins BJ Chemokines. Blood 1997, 90:909-928.
90. Cairns JS, D'Souza MP Chemokines and HIV-1 second receptors: the therapeutic connection. Nat Med 1998, 4:563-568.
91. Reinhardt PP, Reinhardt B, Lathey JL, Spector SA Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates. J Clin Microbiol 1995, 33:292-297.
92. Panganiban AT Retroviral reverse transcription and DNA integration. Virology 1990, 1:187-194.
93. Bushman FD, Fujiwara T, Craigie R Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990, 249:1555-1558.
94. Brown PO, Bowerman B, Varmus HE, Bishop JM Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc Natl Acad Sci U S A 1989, 86:2525-2529.
95. Stevenson M, Haggerty S, Lamonica CA, et al. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990, 64:2421-2425.
96. Bagasra O, Hauptman SP, Lischner HW, et al. Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med 1992, 326:1385-1391.
97. Chevret S, Kirstetter M, Mariotti M, et al. Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994, 169:882-885.
98. Ho DD Dynamics of HIV-1 replication in vivo. J Clin Invest 1997, 99:2565-2567.
99. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
100. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
101. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
102. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988, 85:4686-4690.
103. Swanstrom R, Kaplan AH, Manchester M The aspartic proteinase of HIV-1. Semin Virol 1990, 1:175-186.
104. Perno C-F, Bergamini A, Pesce CD, et al. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J Infect Dis 1993, 168:1148-1156.
105. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997, 336:1337-1342.
106. Palumbo PE, Kwok S, Wesley Y, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995, 126:592-595.
107. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997, 175:1029-1038.
108. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998, 178:101-108.
109. McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996, 15:1087-1091.
110. Balotta C, Colombo MC, Colucci G, et al. Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1997, 16:205-211.
111. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
112. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
113. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics 2000, 105:e8.
114. Bryson YJ, Pang S, Wei LS, et al. Clearance of HIV infection in a perinatally infected infant. N Engl J Med 1995, 332:833-838.
115. Bryson YJ HIV clearance in infants-a continuing saga. AIDS 1995, 9:1373-1375.
116. Roques PA, Gras G, Parnet-Mathieu F, et al. Clearance of HIV infection in 12 perinatally infected children: clinical, virological and immunological data. AIDS 1995, 9:F19-F26.
117. Lepage P, Van de Perre P, Simonon A, et al. Transient seroreversion in children born to human immunodeficiency virus 1-infected mothers. Pediatr Infect Dis J 1992, 11:892-894.
118. Bakshi SS, Tetali S, Abrams EJ, et al. Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed seroreverting infants. Pediatr Infect Dis J 1995, 14:658-662.
119. Frenkel LM, Mullins JI, Learn GH, et al. Genetic evaluation of suspected cases of transient HIV-1 infection of infants. Science 1998, 280:1073-1077.
120. Erkeller-Yuksel FM, Deneys V, Hannet I, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992, 120:216-222.
121. Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected mothers. Pediatr Infect Dis J 1992, 11:1018-1026. The European Collaborative Study.
122. Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997, 130:388-393.
123. McKinney RE, Wilfert CM Lymphocyte subsets in children younger than 2 years old: normal values in a population at risk for human immunodeficiency virus infection and diagnostic and prognostic application to infected children. Pediatr Infect Dis J 1992, 11:639-644.
124. Dickover RE, Dillon M, Gillette SG, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994, 170:1279-1284.
125. Roilides E, Black C, Reimer C, et al. Serum immunoglobulin G subclasses in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1991, 10:134-139.
126. Luzuriaga K, Koup RA, Pikora CA, et al. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 1991, 119:230-236.
127. Monforte ADA, Novati R, Galli M, et al. T-cell subsets and serum immunoglobulin levels in infants born to HIV-seropositive mothers: a longitudinal evaluation. AIDS 1990, 4:1141-1144.
128. Borkowsky W, Rigaud M, Krasinski K, et al. Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life. J Pediatr 1992, 120:371-375.
129. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991, 337:253-260. European Collaborative Study.
130. Luzuriaga K, Holmes D, Hereema A, et al. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995, 154:433-443.
131. Pikora CA, Sullivan JL, Panicali D, Luzuriaga K Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected children. J Exp Med 1997, 185:1153-1161.
132. Kline MW, Lewis DE, Hollinger FB, et al. A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1994, 13:90-94.
133. Comeau AM, Pitt J, Hillyer GV, et al. Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. J Pediatr 1996, 129:111-118.
134. Horsburgh CR, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989, 2:637-640.
135. Rogers MF, Ou C-Y, Kilbourne B, Schochetman G Advances and problems in the diagnosis of human immunodeficiency virus infection in infants. Pediatr Infect Dis J 1991, 10:523-531.
136. Chantry CJ, Cooper ER, Pelton SI, et al. Seroreversion in human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J 1995, 14:382-387.
137. Tudor-Williams G Early diagnosis of vertically acquired HIV-1 infection. AIDS 1991, 5:103-105.
138. Yanase Y, Tango T, Okumura K, et al. Lymphocyte subsets identified by monoclonal antibodies in healthy children. Pediatr Res 1986, 20:1147-1151.
139. Quinn TC, Ruff A, Halsey N Pediatric acquired immunodeficiency syndrome: special considerations for developing nations. Pediatr Infect Dis J 1992, 11:558-568.
140. Pollack H, Glasberg H, Lee E, et al. Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr 1997, 130:915-922.
141. Blanche S, Tardieu M, Duliege A-M, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Am J Dis Child 1990, 144:1210-1215.
142. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987, 36(Suppl 1S):1S-15S. Centers for Disease Control.
143. Andiman WA, Mezger J, Shapiro E Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr 1994, 124:846-852.
144. Lichenstein R, King JC, Farley JJ, et al. Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings. Pediatr Infect Dis J 1998, 17:381-385.
145. Janoff EN, Breiman RE, Daley CL, Hopewell PC Pneumococcal disease during HIV infection: epidemiology, clinical, and immunologic perspectives. Ann Intern Med 1992, 117:314-324.
146. Farley JJ, King JC, Nair P, et al. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr 1994, 124:853-858.
147. Di John D, Krasinski K, Lawrence R, et al. Very late onset of group B streptococcal disease in infants infected with the human immunodeficiency virus. Pediatr Infect Dis J 1990, 9:925-928.
148. Dorfman DH, Glaser JH Congenital syphilis presenting in infants after the newborn period. N Engl J Med 1990, 323:1299-1302.
149. Dumois JA Potential problems with the diagnosis and treatment of syphilis in HIV-infected pregnant women. Pediatr AIDS HIV Infect Fetus Adolesc 1992, 3:22-24.
150. McIntosh K Congenital syphilis-breaking through the safety net. N Engl J Med 1990, 323:1339-1341.
151. Screening for tuberculosis and tuberculous infection in high-risk populations and the use of preventive therapy for tuberculous infections in the United States. MMWR Morb Mortal Wkly Rep 1990, 39:1-12. Centers for Disease Control.
152. Khoury YF, Mastrucci MT, Hutto C, et al. Mycobacterium tuberculosis in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1992, 11:950-955.
153. Gutman LT, Moye J, Zimmer B, Tian C Tuberculosis in human immunodeficiency virus-exposed or -infected United States children. Pediatr Infect Dis J 1994, 13:963-968.
154. Screening for tuberculosis in infants and children. Pediatrics 1994, 93:131-134. Committee on Infectious Diseases.
155. Adhikari M, Pillay T, Pillay DG Tuberculosis in the newborn: an emerging disease. Pediatr Infect Dis J 1997, 16:1108-1112.
156. Update on tuberculosis skin testing of children. Pediatrics 1996, 97:282-284. Committee on Infectious Diseases.
157. Starke JR, Correa AG Management of mycobacterial infection and disease in children. Pediatr Infect Dis J 1995, 14:455-470.
158. Lewis LL, Butler KM, Husson RN, et al. Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infection. J Pediatr 1992, 121:677-683.
159. Rutstein RM, Cobb P, McGowan KL, et al. Mycobacterium avium intracellulare complex infection in HIV-infected children. AIDS 1993, 7:507-512.
160. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997, 46:1-46. USPHS/IDSA Prevention of Opportunistic Infections Working Group.
161. Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1989, 8:586-590.
162. Silliman CC, Tedder D, Ogle JW, et al. Unsuspected varicella-zoster virus encephalitis in a child with acquired immunodeficiency syndrome. J Pediatr 1993, 123:418-422.
163. Lyall EG, Ogilvie MM, Smith NM, Burns S Acyclovir resistant varicella zoster and HIV infection. Arch Dis Child 1994, 70:133-135.
164. Chandwani S, Kaul A, Bebenroth D, et al. Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1996, 15:310-314.
165. Nigro G, Krysztofiak A, Castelli Gattinara G, et al. Rapid progression of HIV disease in children with cytomegalovirus DNAemia. AIDS 1996, 10:1127-1133.
166. Doyle M, Atkins JT, Rivera-Matos IR Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1996, 15:1102-1106.
167. Kitchen BJ, Engler HD, Gill VJ, et al. Cytomegalovirus infection in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997, 16:358-363.
168. Zaknun D, Zangerle R, Kapelari K, et al. Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Pediatr Infect Dis J 1997, 16:807-811.
169. Walton RC, Whitcup SM, Mueller BU, et al. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. Ophthalmology 1995, 102:1865-1870.
170. Bodsworth NJ, Cooper DA, Donovan B The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
171. Eyster ME, Diamondstone LS, Lien J-M, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of co-infection with human immunodeficiency virus. J Acquir Immune Defic 1993, 6:602-610.
172. Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995, 14:195-199.
173. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000, 31:751-755.
174. Resti M, Azzari C, Galli L, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002, 185:567-572. Epub Feb 14, 2002.
175. Kaplan LJ, Daum RS, Smaron M, McCarthy CA Severe measles in immunocompromised patients. JAMA 1992, 267:1237-1241.
176. Palumbo P, Hoyt L, Demasio K, et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992, 11:1008-1014.
177. Nadel S, McGann K, Hodinka RL, et al. Measles giant cell pneumonia in a child with human immunodeficiency virus infection. Pediatr Infect Dis J 1991, 10:542-544.
178. Krasinski K, Borkowsky W Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989, 261:2512-2516.
179. Chandwani S, Borkowsky W, Krasinski K, et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990, 117:251-254.
180. Ellaurie M, Schutzbank TE, Rakusan TA, Lipson SM Spectrum of adenovirus infection in pediatric HIV infection. Pediatr AIDS HIV Infect 1993, 4:211-214.
181. King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993, 12:733-739.
182. Joshi VV, Kauffman S, Oleske JM, et al. Polyclonal polymorphic B-cell lymphoproliferative disorder with prominent pulmonary involvement in children with acquired immune deficiency syndrome. Cancer 1987, 59:1455-1462.
183. Gonzales CE, Venson D, Lee S, et al. Risk factors for fungemia in children infected with human immunodeficiency virus: a case control
184. Leggiadro RJ, Kline MW, Hughes WT Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991, 10:658-662.
185. Gonzales GE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996, 15:796-800.
186. Minamoto GY, Barlam TF, Vander Els NJ Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1992, 14:66-74.
187. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:654-662.
188. Shetty D, Giri N, Gonzales CE, et al. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis 1997, 16:216-221.
189. Sarosi GA, Johnson PC Disseminated histoplasmosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1992, 14(Suppl 1):S60-S67.
190. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992, 116:847-853.
191. Byers M, Feldman S, Edwards J Disseminated histoplasmosis as the acquired immunodeficiency syndrome-defining illness in an infant. Pediatr Infect Dis J 1992, 11:127-128.
192. Simonds RJ, Oxtoby MJ, Caldwell B, et al. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993, 270:470-473.
193. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1995, 44:1-12. Centers for Disease Control and Prevention.
194. HIV AIDS Surveill Rep 1997, 9:1-43. Centers for Disease Control and Prevention.
195. Mortier E, Pouchot J, Bossi P, Molinié V Maternal-fetal transmission of Pneumocystis carinii in human immunodeficiency virus infection. N Engl J Med 1995, 332:825-826.
196. Bye MR, Bernstein LJ, Glaser J, Kleid D Pneumocystis carinii pneumonia in young children with AIDS. Pediatr Pulmonol 1990, 9:251-253.
197. Connor E, Bagarazzi M, McSherry G, et al. Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV. JAMA 1991, 265:1693-1697.
198. Gosey LL, Howard RM, Witebsky FG, et al. Advantages of a modified toluidine blue O stain and bronchoalveolar lavage for the diagnosis of Pneumocystis carinii pneumonia. J Clin Microbiol 1985, 22:803-807.
199. Ognibene FP, Gill VJ, Pizzo PA, et al. Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients. J Pediatr 1989, 115:430-433.
200. Sattler FR, Cowan R, Nielsen DM, Ruskin J Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988, 109:280-287.
201. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1444-1450.
202. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 1323:1451-1457.
203. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1500-1504. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia.
204. McLaughlin GE, Virdee SS, Schleien CL, et al. Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure. J Pediatr 1995, 126:821-824.
205. Bernstein LJ, Bye MR, Rubinstein A Prognostic factors and life expectancy in children with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am J Dis Child 1989, 143:775-778.
206. Kovacs A, Frederick T, Church J, et al. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA 1991, 265:1698-1703.
207. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1991, 40:1-13. Centers for Disease Control.
208. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995, 332:786-790.
209. Thea DM, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996, 97:59-64.
210. Mueller BU, Butler KM, Husson RN, Pizzo PA Pneumocystis carinii pneumonia despite prophylaxis in children with human immunodeficiency virus infection. J Pediatr 1991, 119:992-994.
211. Nachman SA, Mueller BU, Mirochnik M, Pizzo PA High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994, 13:1004-1006.
212. Mitchell CD Toxoplasmosis. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 419-431. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
213. Mitchell CD, Erlich SS, Mastrucci MT, et al. Congenital toxoplasmosis occurring in infants infected with human immunodeficiency virus 1. Pediatr Infect Dis J 1990, 9:512-518.
214. Medlock MD, Tilleli JT, Pearl GS Congenital cardiac toxoplasmosis in a newborn with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1990, 9:129-132.
215. Cordell RL, Addiss DG Cryptosporidiosis in child care settings: a review of the literature and recommendations for prevention and control. Pediatr Infect Dis J 1994, 13:310-317.
216. Mueller BU Cancers in human immunodeficiency virus-infected children. J Natl Cancer Inst Monogr 1998, 23:31-35.
217. Siskin GP, Haller JO, Miller S, Sundaram R AIDS-related lymphoma: Radiologic features in pediatric patients. Radiology 1995, 196:63-66.
218. Nadal D, Caduff R, Frey E, et al. Non-Hodgkin's lymphoma in four children infected with the human immunodeficiency virus. Cancer 1994, 73:224-230.
219. Granovsky MO, Mueller BU, Nicholson HS, et al. HIV-associated tumors in children: a case series from the Children's Cancer Group and National Cancer Institute, Tenth Annual Meeting of the American Society of Pediatric Hematology/Oncology, San Francisco, CA, September 10-20, 1997.
220. Connor E, Boccon-Gibod L, Joshi V, et al. Cutaneous acquired immunodeficiency syndrome-associated Kaposi's sarcoma in pediatric patients. Arch Dermatol 1990, 126:791-793.
221. Buck BE, Scott GB, Valdes-Dapena M, Parks WP Kaposi sarcoma in two infants with acquired immune deficiency syndrome. J Pediatr 1983, 103:911-913.
222. Gutierrez-Ortega P, Hierro-Orozco S, Sanchez-Cisneros R, Montana LF Kaposi's sarcoma in a 6-day-old infant with human immunodeficiency virus. Arch Dermatol 1989, 125:432-433.
223. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 1995, 332:12-18.
224. Jenson HB, Leach CT, McClain KL, et al. Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:A49.
225. Lobato MN, Caldwell MB, Ng P, et al. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1995, 126:710-715.
226. Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:221-228.
227. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr 1998, 132:808-812.
228. Neurologic signs in young children with human immunodeficiency virus infection. Pediatr Infect Dis J 1990, 9:402-406. The European Collaborative Study.
229. Park YD, Belman AL, Kim T-S, et al. Stroke in pediatric acquired immunodeficiency syndrome. Ann Neurol 1990, 28:303-311.
230. Lang C, Jacobi G, Kreuz W, et al. Rapid development of giant aneurysm at the base of the brain in an 8-year-old boy with perinatal HIV infection. Acta Histochem Suppl 1992, 42:S83-S90.
231. Belman AL, Diamond G, Dickson D, et al. Pediatric acquired immunodeficiency syndrome: neurologic symptoms. Am J Dis Child 1988, 142:29-35.
232. Epstein LG, Sharer LR, Goudsmit J Neurological and neuropathological features of human immunodeficiency virus infection in children. Ann Neurol 1988, 23(Suppl):S19-S23.
233. Gay GL, Armstrong FD, Cohen D, et al. The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months. Pediatrics 1995, 96:1078-1082.
234. Wolters PL, Brouwers P, Moss HA, Pizzo PA Differential receptive and expressive language functioning of children with symptomatic HIV disease and relation to CT scan brain abnormalities. Pediatrics 1995, 95:112-119.
235. Brouwers P, Belman A, Epstein L Central nervous system involvement: manifestations, evaluation, and pathogenesis. Pediatric AIDS. The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 433-455. Williams & Wilkins, Baltimore. P.A. Pizzo, C.A. Wilfert (Eds.).
236. Brouwers P, DeCarli C, Civitello L, et al. Correlation between computed tomographic brain scan abnormalities and neuropsychological function in children with symptomatic human immunodeficiency virus disease. Arch Neurol 1995, 52:39-44.
237. Brouwers P, DeCarli C, Tudor-Williams G, et al. Interrelations among patterns of change in neurocognitive, CT brain imaging and CD4 measures associated with anti-retroviral therapy in children with symptomatic HIV infection. Adv Neuroimmunol 1994, 4:223-231.
238. DeCarli C, Civitello LA, Brouwers P, Pizzo PA The prevalence of computed tomographic abnormalities of the cerebrum in 100 consecutive children symptomatic with the human immunodeficiency virus. Ann Neurol 1993, 34:198-205.
239. DeCarli C, Fugate L, Falloon J, et al. Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of continuous infusion zidovudine therapy. J Acquir Immune Defic Syndr 1991, 4:585-592.
240. Sharer LR, Saito Y, Epstein LG, Blumberg BM Detection of HIV-1 DNA in pediatric AIDS brain tissue by two-step ISPCR. Adv Neuroimmunol 1994, 4:283-285.
241. Sharer LR Neuropathological aspects of HIV-1 infection in children. The Neurology of AIDS 1998, 408-418. Chapman & Hall, New York. H.E. Gendelman, S.A. Lipton, L. Epstein, S. Swindells (Eds.).
242. Saito Y, Sharer LR, Epstein LG, et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 1994, 44:474-481.
243. Baba TW, Liska V, Ruprecht RM HIV-1/SIV infection of the fetal and neonatal nervous system. The Neurology of AIDS 1998, 443-456. Chapman & Hall, New York. H.E. Gendelman, S.A. Lipton, L. Epstein, S. Swindells (Eds.).
244. Pratt RD, Nichols S, McKinney N, et al. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. J Infect Dis 1996, 174:288-293.
245. Sei S, Stewart SK, Farley M, et al. Evaluation of HIV-1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996, 174:1200-1206.
246. Gelbard HA HIV-1-induced neurotoxicity in the developing central nervous system. The Neurology of AIDS 1998, 419-424. Chapman & Hall, New York. H.E. Gendelman, S.A. Lipton, L. Epstein, S. Swindells (Eds.).
247. Brouwers P, Heyes MP, Moss HA, et al. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. J Infect Dis 1993, 168:1380-1386.
248. Sei S, Saito K, Stewart SK, et al. Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. J Infect Dis 1995, 172:638-647.
249. Srugo I, Wittek AE, Israele V, Brunell PA Meningoencephalitis in a neonate congenitally infected with human immunodeficiency virus type 1. J Pediatr 1992, 120:93-95.
250. Sharer LR, Dowling PC, Michaels J, et al. Spinal cord disease in children with HIV-1 infection: a combined molecular biological and neuropathological study. Neuropathol Appl Neurobiol 1990, 16:317-331.
251. Brouwers P, Moss H, Wolters P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990, 117:980-985.
252. Stiehm ER, Bryson YJ, Frenkel LM, et al. Prednisone improves human immunodeficiency virus encephalopathy in children. Pediatr Infect Dis J 1992, 11:49-50.
253. Cunningham ET, Margolis TP Ocular manifestations of HIV infection. N Engl J Med 1998, 339:236-244.
254. de Smet MD, Nussenblatt RB Ocular manifestations of HIV in pediatric populations. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 457-466. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
255. Bottoni F, Gonnella P, Autelitano A, Orzalesi N Diffuse necrotizing retinochoroiditis in a child with AIDS and toxoplasmic encephalitis. Graefes Arch Clin Exp Ophthalmol 1990, 228:36-39.
256. Lopez JS, deSmet MD, Masur H, et al. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1992, 113:331-333.
257. Telzak EE, Cote RJ, Gold JWM, et al. Extrapulmonary Pneumocystis carinii infections. Rev Infect Dis 1990, 12:380-386.
258. Connor EM, Andiman WA Lymphoid interstitial pneumonitis. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 467-482. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
259. Sharland M, Gibb DM, Holland F Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997, 76:334-336.
260. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989, 321:1791-1796.
261. Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE Cardiac morbidity and related mortality in children with HIV infection. JAMA 1993, 269:2869-2875.
262. Lipshultz SE, Orav EJ, Sanders SP, et al. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992, 327:1260-1265.
263. Lipshultz SE, Fox CH, Perez-Atayde AR, et al. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. Am J Cardiol 1990, 66:246-250.
264. Joshi VV, Gadol C, Connor E, et al. Dilated cardiomyopathy in children with acquired immunodeficiency syndrome: a pathologic study of five cases. Hum Pathol 1988, 19:69-73.
265. Lewis W AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 1989, 32:207-215.
266. Grody WW, Cheng L, Lewis W Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990, 66:203-206.
267. Joshi VV, Pawel B, Connor E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987, 7:261-275.
268. Kure K, Park YD, Kim T-S, et al. Immunohistochemical localization of an HIV epitope in cerebral aneurysmal arteriopathy in pediatric acquired immunodeficiency syndrome (AIDS). Pediatr Pathol 1989, 9:655-667.
269. Husson RN, Saini R, Lewis LL, et al. Cerebral artery aneurysms in children infected with human immunodeficiency virus. J Pediatr 1992, 121:927-930.
270. Galli L, de Martino M, Tovo P-A, et al. Onset of clinical signs in children with HIV-1 perinatal infection. AIDS 1995, 9:455-461.
271. Pickering LK Infections of the gastrointestinal tract. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 377-404. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
272. Yolken RH, Li S, Perman J, Viscidi R Persistent diarrhea and fecal shedding of retroviral nucleic acids in children infected with human immunodeficiency virus. J Infect Dis 1991, 164:61-66.
273. Grunfeld C, Feingold KR Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
274. Lewis JD, Winter HS Intestinal and hepatobiliary diseases in HIV-infected children. Gastroenterol Clin North Am 1995, 24:119-132.
275. Kotloff KL, Johnson JP, Nair P, et al. Diarrheal morbidity during the first 2 years of life among HIV-infected infants. JAMA 1994, 271:448-452.
276. Thea DM, St.Louis ME, Atido U, et al. A prospective study of diarrhea and HIV-1 infection among 429 Zairian infants. N Engl J Med 1993, 329:1696-1702.
277. Miller TL Nutritional assessment and its clinical application in children infected with the human immunodeficiency virus. J Pediatr 1996, 129:633-636.
278. Leggiadro RJ, Lewis D, Whitington GL, et al. Chronic hepatitis associated with perinatal HIV infection. AIDS Reader 1992, March/April:57-61.
279. Persaud D, Bangaru B, Greco A, et al. Cholestatic hepatitis in children infected with the human immunodeficiency virus. Pediatr Infect Dis J 1993, 12:492-498.
280. Miller TL, Winter HS, Luginbuhl LM, et al. Pancreatitis in pediatric human immunodeficiency virus infection. J Pediatr 1992, 120:223-227.
281. Butler KM, Venzon D, Henry N, et al. Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics 1993, 91:747-751.
282. Strauss J, Abitol C, Zilleruelo G, et al. Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med 1989, 321:625-630.
283. Strauss J, Zilleruelo G, Abitbol C, et al. Human immunodeficiency virus nephropathy. Pediatr Nephrol 1993, 7:220-225.
284. Ingulli E, Tejani A, Fikrig S, et al. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991, 119:710-716.
285. Schoeneman MJ, Ghali V, Lieberman K, Reisman L IgA nephritis in a child with human immunodeficiency virus: a unique form of human immunodeficiency virus-associated nephropathy?. Pediatr Nephrol 1992, 6:46-49.
286. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: Idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:702-706.
287. Mueller BU, Sleasman J, Nelson RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998, 102:101-109.
288. Bruce RG, Munch LC, Hoven AD, et al. Urolithiasis associated with the protease inhibitor indinavir. Urology 1997, 50:513-518.
289. Gertner JM, Kaufman FR, Donfield SM, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994, 124:896-902.
290. Fisher GD, Rinaldo CR, Gbadero D, et al. Seroprevalence of HIV-1 and HIV-2 infection among children diagnosed with protein-calorie malnutrition in Nigeria. Epidemiol Infect 1993, 110:373-378.
291. Brettler DB, Forsberg A, Bolivar E, et al. Growth failure as a prognostic indicator for progression to acquired immunodeficiency syndrome in children with hemophilia. J Pediatr 1990, 117:584-588.
292. Laue L, Pizzo PA, Butler K, Cutler GB Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr 1990, 117:541-545.
293. Schwartz LJ, St.Louis Y, Wu R, et al. Endocrine function in children with human immunodeficiency virus infection. Am J Dis Child 1991, 145:330-333.
294. Grinspoon SK, Bilezikian JP HIV disease and the endocrine system. N Engl J Med 1992, 327:1360-1365.
295. Hirschfeld S, Laue L, Cutler GB, Pizzo PA Thyroid abnormalities in children infected with human immunodeficiency virus. J Pediatr 1996, 128:70-74.
296. Papiernik M, Brossard Y, Mulliez N, et al. Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropositive women. Pediatrics 1992, 89:297-301.
297. Joshi VV, Oleske JM, Saad S, et al. Thymus biopsy in children with acquired immunodeficiency syndrome. Arch Pathol Med 1986, 110:837-842.
298. Sei S, Kleiner DE, Kopp JB, et al. Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. J Infect Dis 1994, 170:325-333.
299. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998, 4:341-345.
300. Pantaleo G, Fauci AS HIV-1 infection in the lymphoid organs: a model of disease development. J NIH Res 1993, 5:68-72.
301. Mueller BU, Sei S, Anderson B, et al. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. J Pediatr 1996, 129:410-418.
302. Scott GB, Buck BE, Leterman JG, et al. Acquired immunodeficiency syndrome in infants. N Engl J Med 1984, 310:76-81.
303. Ellaurie M, Burns ER, Rubinstein A Hematologic manifestations in pediatric HIV infection: severe anemia as a prognostic factor. Am J Pediatr Hematol Oncol 1990, 12:449-453.
304. Mueller BU Hematological problems and their management in children with HIV infection. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 591-602. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
305. Forsyth BW, Andiman WA, O'Connor T Development of a prognosis-based clinical staging system for infants infected with human immunodeficiency virus. J Pediatr 1996, 129:648-655.
306. Mueller BU, Tannenbaum S, Pizzo PA Bone marrow aspirates and biopsies in children with human immunodeficiency virus infection. J Pediatr Hematol Oncol 1996, 18:266-271.
307. Parmentier L, Boucary D, Salmon D Pure red cell aplasia in an HIV-infected patient. AIDS 1992, 6:234-235.
308. Nigro G, Castelli Gattinara G, et al. Parvovirus-B19-related pancytopenia in children with HIV infection. Lancet 1992, 340:115.
309. Abkowitz JL, Brown KE, Wood RW, et al. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997, 176:269-273.
310. Holodniy M, Margolis D, Carroll R, et al. Quantitative relationship between platelet count and plasma virion HIV RNA. AIDS 1996, 10:232-233.
311. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:1779-1789.
312. Rigaud M, Leibovitz E, Sin Quee C, et al. Thrombocytopenia in children infected with human immunodeficiency virus: long-term follow-up and therapeutic considerations. J Acquir Immune Defic Syndr 1992, 5:450-455.
313. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and the coagulation proteins in AIDS. Thromb Haemost 1997, 77:856-861.
314. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection: the role of anticardiolipin and anti-protein S antibodies. Thromb Res 1994, 73:165-175.
315. Rodriguez-Mahou M, Lopez-Longo J, Lapointe N, et al. Autoimmune phenomena in children with human immunodeficiency virus infection and acquired immunodeficiency syndrome. Acta Paediatr Suppl 1994, 400:31-34.
316. Coopman SA, Johnson RA, Platt R, Stern RS Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993, 328:1670-1674.
317. Prose NS Skin problems. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents 1994, 535-546. Williams & Wilkins, Baltimore. P.A. Pizzo, C.M. Wilfert (Eds.).
318. von Seidlein L, Gillette SG, Bryson Y, et al. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr 1996, 128:52-57.
319. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:442-450.
320. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
321. Jean SS, Reed GW, Verdier R-I, et al. Clinical manifestations of human immunodeficiency virus infection in Haitian children. Pediatr Infect Dis J 1997, 16:600-606.
322. Braddick MR, Kreiss JK, Embree JE, et al. Impact of maternal HIV infection on obstetrical and early neonatal outcome. AIDS 1990, 4:1001-1005.
323. Moye J, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group. J Pediatr 1996, 128:58-69.
324. Frederick T, Mascola L, Eller A, et al. Progression of human immunodeficiency virus disease among infants and children infected perinatally with human immunodeficiency virus or through neonatal blood transfusion. Pediatr Infect Dis J 1994, 13:1091-1097.
325. Blanche S, Mayaux M-J, Rouzioux C, et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994, 330:308-312.
326. Blanche S, Rouzioux C, Guihard Moscato M-L, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N Engl J Med 1989, 320:1643-1648.
327. Mayaux M-J, Burgard M, Teglas J-P, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996, 275:606-610.
328. Zaknun D, Orav J, Kornegay J, et al. Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. J Pediatr 1997, 130:898-905.
329. Dickover RE, Dillon M, Leung KM, et al. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis 1998, 178:375-387.
330. Reducing the Odds-Preventing Perinatal Transmission of HIV in the United States 1999, National Academy Press, Washington, DC. M.A. Stoto, D.A. Almario, M.C. McCormik (Eds.).
331. Peters V, Liu KL, Dominguez K, et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort. Pediatrics 2003, 111:1186-1191.
332. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998, 178:101-108.
333. Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994, 343:1464-1467. The European Collaborative Study.
334. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999, 353:1035-1039. The European Mode of Delivery Collaboration.
335. Ricci E, Parazzini F, Pardi G Caesarean section and antiretroviral treatment. Italian trial on mode of delivery in HIV-positive women study group. Lancet 2000, 355:496.
336. Lindegren ML, Byers RH, Thomas P, Davis SF, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999, 282:531. 318.
337. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med 2002, 156:915-921. Italian Register for Human Immunodeficiency Virus Infection in Children.
338. Lurie P, Wolfe SM Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997, 337:853-856.
339. Mofenson LM, Burns DN Passive immunization to prevent mother-infant transmission of human immunodeficiency virus: current issues and future directions. Pediatr Infect Dis J 1991, 10:456-462.
340. Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 1997, 175:283-291.
341. Bertolli J, Hu DJ, Nieburg P, et al. Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV. AIDS 2003, 17:2089-2098.
342. WHO. Breastfeeding and replacement feeding practices in the context of mother-to-child transmission of HIV-an assessment tool for research. RHR/01.12, 2001.
343. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999, 179:567-575.
344. Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics 1994, 93:682-685. American Academy of Pediatrics Committee on Infectious Diseases.
345. Adamson PC, Wu TC, Meade BD, et al. Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr 1989, 115:598. 592.
346. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991, 325:73-80. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group.
347. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adolescents and Adults Panel on Clinical Practices for Treatment of HIV Infection, accessed January 2004. http://aidsinfo.nih.gov/guidelines/.
348. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, accessed January 2004. http://aidsinfo.nih.gov/guidelines/.
349. Antiretroviral therapy and medical management of pediatric HIV infection. Pediatrics 1998, 102:1005-1085. Working Group on Antiretroviral Therapy and Medical Management of Infants, Children, and Adolescents with HIV Infection.
350. Lyman WD, Tanaka KE, Kress Y, et al. Zidovudine concentrations in human fetal tissue: implications for perinatal AIDS. Lancet 1990, 335:1280-1281.
351. Garland M, Szeto HH, Daniel SS, et al. Placental transfer and fetal metabolism of zidovudine in the baboon. Pediatr Res 1998, 44:47-53.
352. Sperling RS, Roboz J, Dische R, et al. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992, 9:247-249.
353. O'Sullivan MJ, Boyer PJJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993, 168:1510-1516.
354. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991, 163:226-232.
355. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer. J Acquir Immune Defic Syndr 1990, 3:959-964.
356. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL Pharmacokinetics of zidovudine (azidothymidine): II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr 1990, 3:1052-1058.
357. Boucher FD, Au DS, Martin DM, et al. Pharmacokinetics and safety of azidothymidine (AZT) in infants less than three months old, exposed at birth to HIV. Clin Res 1989, 37:190A.
358. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993, 122:137-144.
359. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3';-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997, 89:1602-1608.
360. Olivero OA, Anderson LM, Diwan BA, et al. AZT is a genotoxic transplacental carcinogen in animal models. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:A29.
361. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused
362. Brady MT, McGrath N, Brouwers P, et al. Randomized study of the tolerance and efficacy of high-versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trial Group 128). J Infect Dis 1996, 173:1097-1106.
363. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992, 165:99-104.
364. Pons JC, Boubon MC, Taburet AM, et al. Fetoplacental passage of 2',3'-dideoxyinosine. Lancet 1991, 337:732.
365. Pereira CM, Nosbisch C, Winter HR, et al. Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. Antimicrob Agents Chemother 1994, 38:781-786.
366. Pereira CM, Nosbisch C, Unadkat JD Pharmacokinetics of dideoxyinosine in neonatal pigtailed macaques. Antimicrob Agents Chemother 1994, 38:787-789.
367. Lai KR, Gang DL, Zawacki JK, Cooley TP Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med 1991, 115:283-284.
368. Whitcup SM, Butler KM, Caruso R, et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. Am J Ophthalmol 1992, 113:1-7.
369. Whitcup S, Butler K, Pizzo P, Nussenblatt R Retinal lesions in children treated with dideoxyinosine. N Engl J Med 1992, 326:1226-1227.
370. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996, 174:16-25.
371. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998, 42:3187-3192.
372. Grob PM, Wu JC, Cohen KA, et al. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retrovir 1992, 8:145-152.
373. Grob PM, Cao Y, Muchmore E, et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med 1997, 3:665-670.
374. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
375. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996, 174:713-721.
376. Shetty AK, Coovadia HM, Mirochnick MM, et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003, 34:482-490.
377. Mirochnik M, Sullivan J, Gagnier P, et al. Safety and pharmacokinetics (PK) of nevirapine in neonates born to HIV-1 infected women. Presented before the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
378. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999, 28:1109-1118.
379. Flexner C HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
380. Mueller BU, Nelson RP, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998, 101:335-343.
381. Havens PL, Cuene BE, Holtgrave DR Lifetime cost of care for children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997, 16:607-610.